Mechanistic models of cancer Mechanistic models cancer-immune cycle and immunotherapies Poster Mechanistic models of cancer Mechanistic models cancer-immune cycle and immunotherapies CertaraJune 24, 2019
Integration of a Tumour Growth Inhibition Model within a Mouse Physiologically-Based Pharmacokinetic Model Poster Integration of a Tumour Growth Inhibition Model within a Mouse Physiologically-Based Pharmacokinetic Model CertaraJune 24, 2019
Optimize Immuno-oncology Drug Discovery and Development Using QSP White Paper Optimize Immuno-oncology Drug Discovery and Development Using QSP A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…CertaraJune 19, 2019
Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement On-Demand Webinar Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease…CertaraMay 13, 2019
Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Poster Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors CertaraMay 2, 2019
Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Poster Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models CertaraApril 22, 2019
Development of a Physiologically-Based Pharmacokinetic Model for Topical Lidocaine in Order to Predict Systemic Absorption in Healthy Volunteers, Geriatrics, and Pediatrics Poster Development of a Physiologically-Based Pharmacokinetic Model for Topical Lidocaine in Order to Predict Systemic Absorption in Healthy Volunteers, Geriatrics, and Pediatrics CertaraApril 22, 2019
Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Poster Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients CertaraApril 22, 2019
Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Poster Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies CertaraApril 22, 2019
Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Poster Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation CertaraApril 22, 2019